Corbus Pharmaceuticals Holdings Inc (LTS:0SZI)

$ 17.106 -1.364 (-7.38%) Market Cap: 204.01 Mil Enterprise Value: 48.25 Mil PE Ratio: 0 PB Ratio: 1.44 GF Score: 28/100

Corbus Pharmaceuticals Holdings Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Corbus Pharmaceuticals Holdings Inc Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corporate Call Transcript
Jun 01, 2021
Q4 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Mar 15, 2021

$69.6 (+5.22%)

Earnings
Q3 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Nov 10, 2020

$32.4 (-3.57%)

Earnings
Corbus Pharmaceuticals Holdings, Inc. - Special Call Transcript
Sep 08, 2020
Q2 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Aug 06, 2020

$194.08 (-8.62%)

Earnings
Q1 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
May 11, 2020

$197.69

Earnings
Q4 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Mar 12, 2020

$197.69

Earnings
Corbus Pharmaceuticals Holdings, Inc. - Special Call Transcript
Dec 13, 2019
Q3 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Nov 07, 2019

$162

Earnings
Q2 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Aug 08, 2019

$178.2

Earnings
Corbus Pharmaceuticals Holdings Inc to Provide an Overview and Clinical Update for Lenabasum Conference Call Transcript
Jun 21, 2019
Q1 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
May 09, 2019

$215.4

Earnings
Full Year 2018 Corbus Pharmaceuticals Holdings Inc Earnings Call Transcript
Mar 12, 2019

$184.8

Earnings

Corbus Pharmaceuticals Holdings, Inc. - Special Call Transcript

Dec 13, 2019 / 06:00PM GMT

Release Date Price: $150

Transcript

Ted Jenkins

Corbus Pharmaceuticals Holdings, Inc. - Senior Director of IR & Communications

Good morning, everyone. I'm Ted Jenkins, Investor Relations at Corbus Pharmaceuticals. We're extremely pleased to have you all join us today as we host an expert symposium discussing the therapeutic potential of targeting the endocannabinoid system. A warm welcome to all of you and to those joining us through our video webcast.

Before we begin, I'd like to remind everyone that today's remarks may contain forward-looking statements, and we encourage you to refer to our filings with the SEC and our corporate website for the latest information on our company.

Additionally, the views will be expressed and the remarks of our guest experts today are their own and not those of Corbus, and Corbus has not participated in the preparation of, nor endorses, their remarks. With regard to Q&A, we ask that you hold your questions until the end of each presentation module, and we are looking forward to spending time with you this afternoon.

And it is now my honor and pleasure to turn the podium

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.